Eli Lilly's blockbuster obesity ​drug Mounjaro became India's ‌top-selling drug by value for the ‌month of October with sales ...

Eli Lilly's weight-loss therapy Mounjaro became India's top-selling drug by value in October, data showed on Friday, ...

Eli Lilly's ( LLY) weight-loss drug, Mounjaro, has become the best-selling medication in India by value as of October, surpassing GSK's ( GSK) antibiotic, Augmentin, a Reuters report said.

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...

The drug has surpassed GlaxoSmithKline’s antibiotic Augmentin, according to a Reuters report on Friday, citing data from ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla Limited have announced a strategic agreement ...

Early results of Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster ...

Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

COPENHAGEN (Reuters) -Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to ...

Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and ...

Eli Lilly's Mounjaro tops India's drug sales in October, surpassing GSK's Augmentin with ₹100 crore in revenue.